BRANY announces launch of Protocol Builder™
Web-based and iPad tablet application solution for writing investigator-initiated research protocols
(Lake Success, NY) - BRANY has announced the launch of Protocol Builder™, a first-of-its-kind solution to assist researchers in the development of investigator-initiated research protocols. This web-based application, accessible from any desktop and iPad tablet, is designed to provide expert guidance and a step-by-step process to make protocol development faster and less onerous. Resources necessary to navigate the elaborate regulatory infrastructure that surrounds clinical research in the U.S. are at researchers’ fingertips in this thoughtfully designed application.
“Many investigators find the regulatory and compliance hurdles difficult and time-consuming to navigate when writing protocols,” says Kimberly Irvine, Executive Vice President and Chief Operating Officer at BRANY. “Protocol Builder ensures efficiency and accuracy in developing a complete protocol, ready to submit to the IRB. By following the guided steps in Protocol Builder, investigators will save time and be better able to provide an omission-free protocol for review. Our objective with Protocol Builder is to use technology to empower researchers to achieve their research goals with less effort.”
Utilizing a team of leading experts in both consumer design and investigator-initiated clinical research, BRANY developed a step-by-step intuitive approach to building a protocol. BRANY has deconstructed the complex process of writing research protocols and designed a tool that’s innovative, packed with time-saving features, yet easy to use.
While many institutions provide templates and training to investigators writing investigator-initiated protocols, research shows a high degree of dissatisfaction with these tools. Protocol Builder reduces the complexities in investigator-initiated protocol development and is an excellent tool for both experienced and new investigators.
Protocol Builder is available to institutions through corporate licenses, and to individual investigators through single user licenses. For more information or to sign up for a free demo, please visit www.protocolbuilderpro.com, or contact (516) 499-5645.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
